View in EDS

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

Saved in:
Bibliographic Details
Title: Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Authors: Stintzing, S.1 sebastian.stintzing@med.uni-muenchen.de, Miller-Phillips, L.1, Modest, D.P.1 Dominik.modest@med.uni-muenchen.de, Fischer von Weikersthal, L.2 weikersthal.ludwig@klinikum-amberg.de, Decker, T.3 t.decker@lrz.tu-muenchen.de, Kiani, A.4 alexander.kiani@klinikum-bayreuth.de, Vehling-Kaiser, U.5 studien@vehling-kaiser.de, Al-Batran, S.-E.6 albatran.salah@khnw.de, Heintges, T.7 heintges@lukasneuss.de, Kahl, C.8 christoph.kahl@klinikum-magdeburg.de, Seipelt, G.9 onkologie-mtk@telemed.de, Kullmann, F.10 frank.kullmann@kliniken-nordoberpfalz.ag, Stauch, M.11 praxisdrstauch@t-online.de, Scheithauer, W.12 werner.scheithauer@meduniwien.ac.at, Held, S.13 s.held@clinassess.de, Moehler, M.14 moehler@mail.uni-mainz.de, Jagenburg, A.15 info@radiology-consulting.com, Kirchner, T.16 Thomas.kirchner@med.uni-muenchen.de, Jung, A.16 Andreas.jung@med.uni-muenchen.de, Heinemann, V.1 Volker.heinemann@med.uni-muenchen.de
Source: European Journal of Cancer. Jul2017, Vol. 79, p50-60. 11p.
Database: Academic Search Ultimate
Description
ISSN:09598049
DOI:10.1016/j.ejca.2017.03.023